C
| Calreticulin Mutation in MPNs, delation & insersion (PCR/Sequencing) |
| Candida albicans |
| CD34 for Stem Cell Enumeration |
| CEBPA Mutation-A as AML prognostic Marker (PCR/Sequencing) |
| CEBPA Mutation-B as AML prognostic Marker (PCR/Sequencing) |
| CEBPA Mutation-C as AML prognostic Marker (PCR/Sequencing) |
| Celiac disease ( HLA DQ2) |
| Celiac disease ( HLA DQ8) |
| Cerebro spinal fluid (CSF)/ culture |
| Chlamydia pneumoniae |
| Chlamydia trachomatis |
| Chlamydia trachomatis |
| c-kit D816V Mutation for AML |
| c-kit D816V Mutation for AML |
| CLL panel at diagnosis (14-16 CD markers) |
| CLL panel for MRD ( 8-12 CD markers) |
| Clostridium difficile |
| C-MET(7q31) for Lung Cancer |
| CML- E255K Mutation or TKI resistance |
| CML- T315I Mutation or TKI resistance |
| CML- Y253H Mutation or TKI resistance |
| CMV (Qualitative) |
| CMV Viral Load (Quantitative) |
| c-MYC amplification (8q24,8cen) for Breast, Cervical, Colon, Ovarian cancers,Myeloma, non-Hodgkin’s lymphoma,Gastric-adenocarcinomas |
| c-MYC Breakapart (8q24) for Burkitt Lymphoma / ALL- L3 |
| Cryptococcus neoformance |
| Cunninghamella |
| Cytology fluid |
| Cytology urine |